Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39,425 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study.
Cheng Y, Wang Q, Li K, Shi J, Liu Y, Wu L, Han B, Chen G, He J, Wang J, Lou D, Yu H, Wang S, Qin H, Li X. Cheng Y, et al. Among authors: yu h. Br J Cancer. 2021 Aug;125(3):366-371. doi: 10.1038/s41416-021-01356-3. Epub 2021 May 18. Br J Cancer. 2021. PMID: 34006926 Free PMC article. Clinical Trial.
[Introduction on "case-sibling control design"].
Yi HG, Chen F, Yu H, Zhao Y, Lou DH. Yi HG, et al. Among authors: yu h. Zhonghua Liu Xing Bing Xue Za Zhi. 2006 Feb;27(2):170-3. Zhonghua Liu Xing Bing Xue Za Zhi. 2006. PMID: 16750003 Chinese.
Therapeutic effect of Jinzhen oral liquid for hand foot and mouth disease: a randomized, multi-center, double-blind, placebo-controlled trial.
Liu J, Zhang GL, Huang GQ, Li L, Li CP, Wang M, Liang XY, Xie D, Yang CM, Li Y, Sun XR, Zhang HS, Wan BS, Zhang WH, Yu H, Zhang RY, Yu YN, Wang Z, Wang YY. Liu J, et al. Among authors: yu yn, yu h. PLoS One. 2014 Apr 10;9(4):e94466. doi: 10.1371/journal.pone.0094466. eCollection 2014. PLoS One. 2014. PMID: 24722423 Free PMC article. Clinical Trial.
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Li J, et al. Among authors: yu h. J Clin Oncol. 2016 May 1;34(13):1448-54. doi: 10.1200/JCO.2015.63.5995. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884585 Clinical Trial.
Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study.
Liu X, Qin S, Wang Z, Xu J, Xiong J, Bai Y, Wang Z, Yang Y, Sun G, Wang L, Zheng L, Xu N, Cheng Y, Guo W, Yu H, Liu T, Lagiou P, Li J. Liu X, et al. Among authors: yu h. J Hematol Oncol. 2017 Sep 5;10(1):153. doi: 10.1186/s13045-017-0521-0. J Hematol Oncol. 2017. PMID: 28870253 Free PMC article.
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.
Ouyang X, Shi M, Jie F, Bai Y, Shen P, Yu Z, Wang X, Huang C, Tao M, Wang Z, Xie C, Wu Q, Shu Y, Han B, Zhang F, Zhang Y, Hu C, Ma X, Liang Y, Wang A, Lu B, Shi Y, Chen J, Zhuang Z, Wang J, Huang J, Wang C, Bai C, Zhou X, Li Q, Chen F, Yu H, Feng J. Ouyang X, et al. Among authors: yu h, yu z. Invest New Drugs. 2018 Apr;36(2):315-322. doi: 10.1007/s10637-017-0536-y. Epub 2017 Nov 14. Invest New Drugs. 2018. PMID: 29134432 Clinical Trial.
39,425 results
You have reached the last available page of results. Please see the User Guide for more information.